Aclarion (ACON) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
The annual meeting is scheduled for July 7, 2025, with voting on four key proposals: election of seven directors, ratification of the independent auditor, approval of a reverse stock split, and amendment to the 2022 Equity Incentive Plan.
Only stockholders of record as of May 9, 2025, are entitled to vote; 582,371 shares are outstanding and eligible.
Proxy materials are primarily distributed online to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposal 1: Elect seven director nominees to serve until the 2026 annual meeting.
Proposal 2: Ratify Haynie & Company as the independent registered public accounting firm for 2025.
Proposal 3: Authorize a reverse stock split at a ratio between 1-for-5 and 1-for-400, at the board's discretion, within one year.
Proposal 4: Approve an amendment to the 2022 Equity Incentive Plan, increasing the share reserve and annual grant limits.
Board recommends voting FOR all proposals.
Shareholders may submit proposals for the 2026 meeting by January 12, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of seven members, with six independent directors as per Nasdaq and SEC rules.
Board committees: audit, compensation, and nominating/corporate governance, each with independent chairs.
Board diversity matrix: 1 female, 6 male directors; all directors attended at least 75% of meetings in 2024.
Lead independent director role established when chairman is also an executive officer.
Code of Business Conduct and Ethics applies to all directors, officers, and employees.
Latest events from Aclarion
- Revenue up 65.6% to $75.7K; net loss $7.2M; $22.6M raised in 2025, $10.4M in 2026.ACON
Q4 202518 Mar 2026 - Non-invasive spinal diagnostics see clinical, commercial, and reimbursement momentum in key markets.ACON
Investor Update23 Jan 2026 - Non-invasive lumbar disc diagnostics show strong outcomes and payer traction, driving expansion.ACON
Investor Update12 Jan 2026 - Shelf registration enables up to $50M in offerings for AI-driven spine diagnostics in a high-need market.ACON
Registration Filing16 Dec 2025 - Healthcare tech firm targets $50M raise amid Nasdaq risks, leveraging patented MRS diagnostics.ACON
Registration Filing16 Dec 2025 - AI-driven diagnostics firm faces Nasdaq risks, offers 27.5M shares for resale, no direct proceeds.ACON
Registration Filing16 Dec 2025 - Up to $150M in securities to fund AI-driven diagnostics for back and neck pain; high risk, high potential.ACON
Registration Filing16 Dec 2025 - Key votes include director elections, auditor ratification, share issuances, and a reverse stock split.ACON
Proxy Filing2 Dec 2025 - Vote sought on a reverse stock split to regain Nasdaq compliance and broaden investor appeal.ACON
Proxy Filing2 Dec 2025